Climb Bio Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Climb Bio Inc.
Former names
Eliem Therapeutics, Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Wellesley Hills
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
CLYM
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001768446
EIN
83-2273741

Board of directors

Follow this board

Chief executives

Aoife Brennan · President and CEO
Dates unknown

Director election results

Annual meeting of June 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 31 other boards.

Network of Climb Bio Inc.'s board connections Vor Biopharma Inc. Vor Biopharma Inc. Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... LENZ Therapeutics Inc. LENZ Therapeutics Inc. Solid Biosciences Inc. Solid Biosciences Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... Mineralys Therapeutics Inc. Mineralys Therapeutics... Nkarta Inc. Nkarta Inc. Alexander Cumbo Alexander Cumbo Andrew David Levin Andrew David Levin Kimberlee C. Drapkin Kimberlee C. Drapkin Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Climb Bio Inc.
Shared director Other board Same sector +15 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$779,626
3 purchases by 2 insiders
Sold, last 12 months
$2,652,762
6 sales by 2 insiders
Date Insider Transaction Shares Price Value
Sep 15, 2026 Stephen Basil Thomas Director Open-market sale −100,000 $13.67 $1,366,820
Jun 29, 2026 Aoife Brennan Director, Officer (President and CEO) Open-market sale −30,902 $13.17 $406,979
Jun 27, 2026 Aoife Brennan Director, Officer (President and CEO) Option exercise +68,750 — —
Feb 26, 2026 Stephen Basil Thomas Director Open-market sale −16,313 $7.01 $114,354
Feb 25, 2026 Stephen Basil Thomas Director Open-market sale −33,687 $7.00 $235,809
Feb 13, 2026 Stephen Basil Thomas Director Open-market sale −10,000 $5.81 $58,100
Feb 12, 2026 Stephen Basil Thomas Director Open-market sale −90,000 $5.23 $470,700
Jan 5, 2026 RA Capital Healthcare Fund LP Director, 10% owner Open-market purchase +7,111 $3.50 $24,889
Dec 12, 2025 Peter Kolchinsky Director, 10% owner Open-market purchase +101,462 $2.86 $290,181
Dec 11, 2025 Peter Kolchinsky Director, 10% owner Sold back to the company −20,440,000 — —
Dec 11, 2025 Peter Kolchinsky Director, 10% owner Open-market purchase +213,099 $2.18 $464,556
Aug 7, 2025 Stephen Basil Thomas Director Grant or award +100,375 — —
Jun 30, 2025 Aoife Brennan Director, Officer (President and CEO) Open-market sale −20,618 $1.22 $25,154
Jun 27, 2025 Aoife Brennan Director, Officer (President and CEO) Option exercise +68,750 — —
Jun 27, 2025 Stephen Basil Thomas Director Option exercise +25,094 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.